[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hae\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hae":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,47,68,97],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":30,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100625889","phase-3-phase-3-extension-study-of-adx-324-in-participants-with-hereditary-angioedema-hae-100625889",false,"NCT07428499","Phase 3 Extension Study of ADX-324 in Participants With Hereditary Angioedema (HAE)","A Phase 3 Extension Study of siRNA Targeting of Prekallikrein With ADX-324 in Participants With Hereditary Angioedema","Inclusion Criteria:\n\n* Have a documented diagnosis of HAE (Type I or II)\n* Completed Study ADX-324-301\n* Have access to an acute therapy to treat HAE attacks (such as plasma derived or recombinant C1-INH concentrate or a BK2-receptor antagonist)\n\nExclusion Criteria:\n\n* A negative reaction to study drug in ADX-324-301","ALL","18 Years",{"count":19,"type":20},90,"ESTIMATED","INTERVENTIONAL",[23],"PHASE3","Study ADX-324-302 is an extension study for participants who complete the Phase 3 ADX-324-301 trial. The extension study will provide information about the safety and efficacy of additional dosing of ADX-324 in participants with Type I and Type II hereditary angioedema (HAE). The study will also include pharmacodynamic (PD), pharmacokinetic (PK), and health-related quality of life (HRQoL) measurements.",[26,27,28,29],"Hereditary Angioedema (HAE)","Hereditary Angioedema - Type 1","Hereditary Angioedema - Type 2","HAE",[31,29,32,33],"Hereditary angioedema","ADX-324","onvuzosiran","RECRUITING","2026-06-12",{"date":37,"type":38},"2026-06-16","ACTUAL",{"date":40,"type":38},"2026-04-02",{"date":42,"type":20},"2030-06-30",{"name":44,"class":45},"ADARx Pharmaceuticals, Inc.","INDUSTRY",48,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":21,"phases":56,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":61,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":67},"100589884","phase-3-stop-hae-a-phase-3-study-of-adx-324-in-hae-100589884","NCT06960213","STOP-HAE: A Phase 3 Study of ADX-324 in HAE","STOP-HAE: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of siRNA Targeting of Prekallikrein With ADX-324 in Participants With Hereditary Angioedema","STOP-HAE","Key Inclusion Criteria:\n\n* Age ≥18 years at the time of signing informed consent.\n* Have a documented diagnosis of HAE-1\u002FHAE-2 (Type I or II)\n* Experience ≥1 Investigator-confirmed HAE attack in the first 4 weeks of Screening or ≥2 Investigator-confirmed HAE attacks in 8 weeks of Screening\n* Able to use at least one acute therapy to treat HAE attacks (such as a plasma-derived or recombinant C1-INH concentrate or a BK2-receptor antagonist)\n\nKey Exclusion Criteria:\n\n* Concurrent diagnosis of another form of recurrent angioedema (such as acquired angioedema, HAE with normal C1-INH (previously known as HAE Type III), idiopathic angioedema, or recurrent angioedema associated with urticaria).\n* Any clinically significant renal disease\n* Any clinically significant hepatic disease\n* Have used any of the following for long-term prevention of HAE attacks:\n\n  1. C1-INH agent (CINRYZE, HAEGARDA, RUCONEST) within 2 weeks prior to Screening.\n  2. Berotralstat (ORLADEYO) within 3 weeks prior to Screening.\n  3. Lanadelumab (TAKHZYRO) within 8 weeks prior to the Screening.\n  4. Androgen use within 12 weeks prior to Screening.\n* Received prior treatment with any RNA\u002FDNA-based therapy for HAE or intolerant to any prior RNA\u002FDNA-based therapy for any condition, excluding vaccines.",{"count":19,"type":20},[23],"This study will evaluate the efficacy and safety of ADX-324 in participants with Type 1 or Type 2 hereditary angioedema. The study will also evaluate safety, pharmacokinetics (PK), pharmacodynamics (PD), and health-related quality of life measures.",[59,29,27,28],"Hereditary Angioedema",[29,31,33],{"date":37,"type":38},{"date":63,"type":38},"2025-08-28",{"date":65,"type":20},"2027-12-31",{"name":44,"class":45},51,{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":74,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":76,"enrollmentInfo":77,"targetDuration":4,"studyType":21,"phases":79,"briefSummary":81,"conditions":82,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":96},"100635972","rectal-arterial-embolization-vs-band-ligation-for-the-treatment-of-internal-hemorrhoids-100635972","NCT07559630","Rectal Arterial Embolization vs Band Ligation for the Treatment of Internal hemOrrhoidS","STRATOS: Single-center Randomized Controlled Trial of Rectal Arterial Embolization vs Band Ligation for the Treatment of Internal hemOrrhoidS","STRATOS","Inclusion Criteria:\n\n1. Age ≥ 18 years and less than 90 years.\n2. Ability to provide written informed consent.\n3. Documented clinical history of chronic bleeding from internal hemorrhoids.\n4. Documented presence of Goligher grade II-III internal hemorrhoids.\n5. Failed conservative treatment for bleeding hemorrhoids (e.g. fiber supplementation, topical ointments and creams, dietary modifications, stool softeners, warm baths).\n6. Able to comply with all treatments and protocol follow-up visits, in the opinion of the PI's.\n\nExclusion Criteria:\n\n1. Moderate loss of kidney function, defined as estimated glomerular filtration rate of less than 45 mL\u002Fmin.\n2. Significant arterial atherosclerosis that would limit selective angiography.\n3. Known alternative causes of GI bleeding.\n4. Allergy to iodinated contrast agents.\n5. Active infection or malignancy.\n6. Pregnancy.\n7. Active nicotine use within the last 12 months.\n8. Portal hypertension\u002Frectal varices.\n9. Uncorrectable coagulopathy (INR \\> 2; Platelet count \\\u003C100,000; PTT \\> 40 sec).\n10. Findings on baseline CTA that adversely affect treatment, based on PI's clinical judgment, including but not limited to stenosis, occlusion, or hypoplasia of the superior and\u002For middle rectal arteries.","89 Years",{"count":78,"type":20},40,[80],"NA","The purpose of this clinical trial is to compare two standard of care non-surgical treatments for hemorrhoidal bleeding: hemorrhoidal artery embolization (HAE) versus rubber band ligation (RBL). Directly comparing these two methods may help to clarify which treatment is better for controlling hemorrhoidal bleeding, reducing symptoms, and improving patients' quality of life.\n\nHAE is a standard minimally invasive procedure to put tiny particles or coils into the blood vessel that feeds a hemorrhoid to block the blood flow (embolization). This involves using a catheter inserted into an artery, using twilight (conscious) sedation.\n\nRBL is a standard procedure that involves using small rubber bands around the base of the hemorrhoids to cut off blood flow, causing it to shrink or shrivel.",[83,84,29,85],"Hemorrhoidal Bleeding","Hemorrhoids, Internal","RBL","2026-05-06",{"date":88,"type":38},"2026-05-08",{"date":90,"type":20},"2026-05-29",{"date":92,"type":20},"2031-11",{"name":94,"class":95},"Jessica K. Stewart, MD","OTHER",1,{"id":98,"slug":99,"hasResults":11,"nctId":100,"briefTitle":101,"officialTitle":101,"acronym":102,"eligibilityCriteria":103,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":104,"enrollmentInfo":105,"targetDuration":4,"studyType":21,"phases":107,"briefSummary":108,"conditions":109,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":96},"100606749","hemorrhoidal-artery-embolization-longitudinal-impact-on-symptoms-helios-100606749","NCT07179601","Hemorrhoidal Artery Embolization: Longitudinal Impact On Symptoms (HELIOS)","HELIOS","Inclusion Criteria:\n\n* Age 18 to 90 years\n* Ability to give written informed consent and to comply with the follow-up visits\n* Symptomatic hemorrhoidal disease with French Bleeding Score (FBS) of at least four out of nine\n* Refusal of or contraindication to surgery\n* Refusal of or contraindication to other minimally invasive hemorrhoid treatments\n* Grade I to III hemorrhoids\n* Previous anoscopy or colonoscopy demonstrating internal hemorrhoids within 1 year\n* Supply of the CCR from either the SRA or MRA on intra-procedural angiogram prior to embolization\n\nExclusion Criteria:\n\n* Asymptomatic patients\n* Patients who ever had previous colorectal surgery\n* Grade IV hemorrhoids\n* Colorectal disease other than hemorrhoids that could result in bleeding\n* Anatomic findings on CTA that would preclude successful embolization\n* Contraindication to iodinated contrast\n* Inability to give written informed consent\n* Active infection or malignancy\n* Recent (within 12 months) or active cigarette use\n* History of inflammatory bowel disease\n* Uncorrectable bleeding diathesis\n* Presence of portal hypertension or rectal varices seen on pre-procedure CTA or anoscopy\u002Fcolonoscopy\n* No SRA or MRA supply to the CCR seen intra-procedural angiogram","90 Years",{"count":106,"type":20},22,[80],"Hemorrhoidal artery embolization (HAE) is a novel treatment for symptomatic internal hemorrhoids. HAE involves the deliberate blockage (embolization) of enlarged rectal or hemorrhoidal arteries leading to reduction of abnormal blood flow to the hemorrhoidal tissue. The aim of HAE is to the improve hemorrhoid related symptoms, especially bleeding. Initial reports of HAE have demonstrated that it both safe and effective. Following an initial clinic visit to determine trial candidacy, enrolled patients will be subsequently treated with HAE. Patients will be followed for a year with clinic follow-up visits at 1, 3, 6 and 12 months.",[110,29],"Internal Hemorrhoids","2026-01-30",{"date":113,"type":38},"2026-02-02",{"date":115,"type":38},"2025-08-05",{"date":117,"type":20},"2029-09-30",{"name":119,"class":95},"University of California, Los Angeles"]